Cagent Vascular Announces FDA 510(k) Clearance for its Serranator Device for the Infrapopliteal Indication and Completion of its PRELUDE-BTK Clinical Trial Enrollment - Business Wire
[unable to retrieve full-text content] Progress on Cardiovascular Disease Care in the U.S. Has Stalled Despite Treatment Advances, New Report Finds The Harvard Crimson
Comments
Post a Comment